Chemo Improves Pain Relief in Advanced Prostate Cancer

Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

PHILADELPHIA--Although the addition of chemotherapy to supportive care with a corticosteroid provides no survival advantage for patients with hormone-refractory prostate cancer, the combination appears to achieve better pain control, compared with corticosteroid therapy alone.

PHILADELPHIA--Although the addition of chemotherapy to supportivecare with a corticosteroid provides no survival advantage forpatients with hormone-refractory prostate cancer, the combinationappears to achieve better pain control, compared with corticosteroidtherapy alone.

The finding, from a phase III Cancer and Leukemia Group B (CALGB)study comparing hydrocortisone with or without mitoxantrone (Novantrone),supports earlier results from a pivotal phase III Canadian trialcomparing prednisone with or without mitoxantrone.

In his presentation of the CALGB preliminary results at the AmericanSociety of Clinical Oncology (ASCO) annual meeting, Phillip W.Kantoff, MD, of the Dana-Farber Cancer Institute, explained thatthe two trials used different primary endpoints.

Palliation and Survival Endpoints

`The Canadian trial (J Clin Oncol 14:1756-1764, 1996), conductedat 11 cancer centers with 161 patients, used palliative responseas the primary endpoint, whereas the CALGB trial, involving 242patients at 62 cancer centers, used survival, with quality oflife, as measured by five different instruments, as a secondaryendpoint.

In the pivotal trial, clinical benefit, defined as reduced painor reduced analgesic use, was seen in 38% of the combination therapygroup versus 21% of the prednisone-alone group. Median durationof pain relief was 8 months among patients who responded to combinationtherapy versus 2 months in the single-agent group.

Immunex Corporation, the maker of Novantrone, has filed thesedata with the Food and Drug Administration to receive priorityreview for use of the drug in hormone-refractory prostate cancer.

Dr. Kantoff reported that the CALGB study demonstrated a generaltrend toward a greater quality of life benefit with the chemotherapyregimen, with two parameters reaching statistical significance:intensity of pain and duration of pain.

As in the pivotal study, chemotherapy was well tolerated. "Grade3 to 4 granulo-cytopenia was frequently encountered in the mitoxantronetherapy arm," Dr. Kantoff said, "but only 2% of patientson mitoxantrone developed grade 3 or higher cardiotoxicity, andthere were no treatment-related deaths reported in either treatmentarm."

In the CALGB study, patients were randomized to receive hydrocortisone,40 mg/day, alone or with mitoxantrone, 14 mg/m² given intravenouslyevery 21 days. Treatment continued until disease progression orlimiting drug toxicity, or to a maximum mitoxantrone dose of 160mg/m².

PSA Decline

In the hydrocortisone-alone arm, 18% of patients had a PSA declineof greater than 50%, compared with 33% in the combination therapyarm, a statistically significant difference in response, Dr. Kantoffreported.

There was a borderline significant benefit for the combinationarm in time to treatment failure. However, he said, there wasno significant difference in overall survival (median, 11.8 monthsfor hydrocortisone alone versus 10.9 months for the combinationarm).

"The results are interesting," Dr. Kantoff said, "andtogether with the Canadian data from Dr. Ian Tannock and his colleagues,the findings support the use of hydrocortisone plus mitoxantronefor the palliation of patients with hormone-refractory prostatecancer." He added, however, that the results "are notsufficiently compelling to regard this combination as a standardof care."

Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Related Content